Ruben de Kanter

3.7k citations

41 papers · 2.7k indexed · 1 hit paper · h-index 23

Co-authors: Geny M. M. Groothuis Marcella Martignoni Marina H. de Jager Peter Olinga Mario Monshouwer Inge A.M. de Graaf Marjolijn T. Merema Esther G. van de Kerkhof
Topics: Pharmacogenetics and Drug Metabolism (18 papers)Drug Transport and Resistance Mechanisms (15 papers)Sphingolipid Metabolism and Signaling (5 papers)
Cited by: Pharmacology Hepatology Oncology
Journals: PEDIATRICS Nature Protocols Journal of Medicinal Chemistry
Partner nations: Switzerland Netherlands Italy

In The Last Decade

Ruben de Kanter

39 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

2006 1.1k citations Marcella Martignoni, Geny M. M. Groothuis et al. profile →

Peers

Countries citing papers authored by Ruben de Kanter

Since Specialization

Citations

This map shows the geographic impact of Ruben de Kanter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruben de Kanter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruben de Kanter more than expected).

Fields of papers citing papers by Ruben de Kanter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruben de Kanter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruben de Kanter. The network helps show where Ruben de Kanter may publish in the future.

Co-authorship network of co-authors of Ruben de Kanter

This figure shows the co-authorship network connecting the top 25 collaborators of Ruben de Kanter. A scholar is included among the top collaborators of Ruben de Kanter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruben de Kanter. Ruben de Kanter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of ACT‐1002‐4271 as a Dual Prostaglandin E2 Receptor 2/Prostaglandin E2 Receptor 4 Antagonist with In Vivo Anti‐Tumor Efficacy 2025 ·ChemMedChem ·Isabelle Lyothier,Stefan Diethelm,(unknown),Thierry Sifferlen,Davide Pozzi,(unknown),(unknown),Heinz Fretz,Christoph Boss,Lorenza Wyder,Sébastien Jeay,Ruben de Kanter,Carmela Gnerre,François Lehembre,Dominique S. Meyer,Olivier Corminboeuf	0
2	Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists 2025 ·ChemMedChem ·Isabelle Lyothier,Stefan Diethelm,(unknown),Thierry Sifferlen,Davide Pozzi,(unknown),(unknown),Heinz Fretz,Christoph Boss,Lorenza Wyder,Sébastien Jeay,Ruben de Kanter,Carmela Gnerre,François Lehembre,Dominique S. Meyer,Olivier Corminboeuf	1
3	925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation 2025 ·Annals of Oncology ·Michael B. Foote,Jingjing Li,Daniel Shao-Weng Tan,Aitana Calvo,Rachel Galot,Elena Garralda,Tormod Kyrre Guren,Antoine Italiano,(unknown),Zev A. Wainberg,Jeffrey Yachnin,Timothy A. Yap,Ruben de Kanter,Nuno Grande,(unknown),Dragana Janković,Laurent Sansregret,Chao Zhang,Ankur K. Nagaraja,Yasutoshi Kuboki	0
4	Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases 2024 ·Journal of Medicinal Chemistry ·Emmanuel A. Meyer,Andrew L. Croxford,Carmela Gnerre,Paulina Kulig,Mark Murphy,(unknown),Gabriel Schäfer,Sylvia Richard‐Bildstein,Hamed Aissaoui,(unknown),Eric A. Ertel,Ruben de Kanter,Marcel P. Keller,Urs Lüthi,(unknown)	4
5	719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors 2023 ·Annals of Oncology ·Michele Moschetta,Toshihiko Doi,Yasutoshi Kuboki,Raghav Sundar,Henrik Möbitz,Isabel Jaco,(unknown),Stéphane Ferretti,(unknown),(unknown),Giuseppe Clementi,(unknown),Ruben de Kanter,Cornelia Quadt	1
6	The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Alexander Treiber,Ruben de Kanter,Catherine Roch,John Gatfield,Christoph Boss,Markus von Raumer,Benno Schindelholz,Clemens Muehlan,Joop van Gerven,François Jenck	69
7	S1P1 Modulator-Induced Gi Signaling and β-Arrestin Recruitment Are Both Necessary to Induce Rapid and Efficient Reduction of Blood Lymphocyte Count In Vivo 2017 ·Molecular Pharmacology ·Magdalena Birker,Martin H. Bolli,Markus Rey,Ruben de Kanter,Christopher Kohl,Cyrille Lescop,(unknown),(unknown),Beat Steiner,Oliver Nayler	4
8	Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines 2016 ·European Journal of Medicinal Chemistry ·Martin H. Bolli,Cyrille Lescop,Magdalena Birker,Ruben de Kanter,Patrick Hess,Christopher Kohl,Oliver Nayler,Markus Rey,Patrick Sieber,(unknown),Thomas Weller,Beat Steiner	12
9	Novel S1P 1 receptor agonists – Part 4: Alkylaminomethyl substituted aryl head groups 2016 ·European Journal of Medicinal Chemistry ·Cyrille Lescop,(unknown),(unknown),Magdalena Birker,Ruben de Kanter,Christopher Kohl,Patrick Hess,Oliver Nayler,Markus Rey,Patrick Sieber,Beat Steiner,Thomas Weller,Martin H. Bolli	11
10	Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold 2012 ·Bioorganic & Medicinal Chemistry Letters ·Claire‐Lise Ciana,Romain Siegrist,Hamed Aissaoui,Léo Marx,Sophie Racine,Solange Meyer,Christoph A. Binkert,Ruben de Kanter,Christoph Fischli,Sergio Wittlin,Christoph Boss	32
11	Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies 2010 ·Nature Protocols ·Inge A.M. de Graaf,Peter Olinga,Marina H. de Jager,Marjolijn T. Merema,Ruben de Kanter,Esther G. van de Kerkhof,Geny M. M. Groothuis	299
12	Induction of drug metabolizing enzymes: A survey of in vitro methodologies and interpretations used in the pharmaceutical industry—Do they comply with FDA recommendations? 2006 ·Chemico-Biological Interactions ·Nicola J. Hewitt,Ruben de Kanter,Edward L. LeCluyse	46
13	An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics 2005 ·Toxicology ·(unknown),Elisa Turlizzi,(unknown),(unknown),Ruben de Kanter,Mario Monshouwer	71
14	A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies 2004 ·Journal of Pharmacological and Toxicological Methods ·Ruben de Kanter,(unknown),Esther van de Kerkhof,Marcella Martignoni,Annelies L. Draaisma,Marina H. de Jager,Inge A.M. de Graaf,Dirk K. F. Meijer,Geny M. M. Groothuis	48
15	An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR 2004 ·Chemico-Biological Interactions ·Marcella Martignoni,Ruben de Kanter,(unknown),(unknown),Grazia Saturno,Mario Monshouwer	52
16	Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation 2003 ·Toxicology in Vitro ·Marcella Martignoni,Mario Monshouwer,Ruben de Kanter,Daniele Pezzetta,(unknown),(unknown)	28
17	Precision-Cut Organ Slices as a Tool to Study Toxicity and Metabolism of Xenobiotics with Special Reference to Non-Hepatic Tissues 2002 ·Current Drug Metabolism ·Ruben de Kanter,Mario Monshouwer,Dirk Meijer,G M Groothuis	93
18	Excess Risk of Severe Acute Illness in Children With Chronic Health Conditions 2001 ·PEDIATRICS ·Nienke P. Dosa,(unknown),(unknown),Ruben de Kanter	114
19	Organ Slices as an In Vitro Test System for Drug Metabolism in Human Liver, Lung and Kidney 1999 ·Toxicology in Vitro ·Ruben de Kanter,Peter Olinga,Marina H. de Jager,Marjolijn T. Merema,Dirk K. F. Meijer,(unknown)	50
20	A rapid and simple method for cryopreservation of human liver slices 1998 ·Xenobiotica ·Ruben de Kanter,Peter Olinga,Ingrid H. Hof,(unknown),(unknown),Maarten J. H. Slooff,Henk Koster,Dirk K. F. Meijer,Geny M. M. Groothuis	40

About Ruben de Kanter

Ruben de Kanter is a scholar working on Pharmacology, Oncology and Biochemistry, having authored 41 papers that have together received 2.7k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (18 papers), Drug Transport and Resistance Mechanisms (15 papers) and Sphingolipid Metabolism and Signaling (5 papers). The work is most often cited by research in Pharmacology (1.0k citations), Hepatology (322 citations) and Oncology (636 citations). Ruben de Kanter has collaborated with scholars based in Switzerland, Netherlands and Italy. Frequent co-authors include Geny M. M. Groothuis, Marcella Martignoni, Marina H. de Jager, Peter Olinga, Mario Monshouwer, Inge A.M. de Graaf, Marjolijn T. Merema, Esther G. van de Kerkhof, Dirk Meijer and Nienke P. Dosa. Their work appears in journals such as PEDIATRICS, Nature Protocols and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact